Damora Therapeutics, Inc. — Form 10-Q
Filed August 10, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 12/100
What the filing says
Damora Therapeutics established three equity plans: (1) 2020 Stock Option and Grant Plan (39,694 shares reserved, no new awards after Oct 2020); (2) 2020 Equity Incentive Plan (67,434 initial shares plus 5% annual increases, up to 8,000,000 total under 2022 Inducement Plan); (3) 2022 Inducement Plan (8,000,000 shares for new employee recruitment). All plans provide stock options, RSUs, restricted stock, and other equity awards to employees, directors, and consultants.
Why this rating
Standard equity plan disclosure. Company scale $4.4M; plan reserve material in absolute terms but routine governance filing, no new economic event or transaction.
See more from August 10, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.